Eli Lilly Expects Up to $87 Billion in 2026 Revenue. Here's Why the Stock Still Looks Undervalued.

Eli Lilly's weight loss drug portfolio, led by Mounjaro and Zepbound, is driving explosive revenue growth with expectations of up to $87 billion in 2026 revenue compared to $65 billion in 2025. Despite a 400% gain over five years and 25% rise in the past six months, the stock trades at 32x forward earnings—below historical levels—and appears undervalued given strong pipeline candidates like EloraTZP and retatrutide that could further expand the company's weight loss drug offerings.